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Somastostatin receptors are frequently expressed in phaeochro-
mocytoma but data on somatostatin receptor subtyping are
scanty and the functional response to the somatostatin analogue
octretide is still debated.We report an unusual case of pheochro-
mocytoma,causing ectopic Cushing’s syndrome due to CRH pro-
duction by the tumour cells, in a 50-yr-old woman. Abdominal
computed tomography revealed an inhomogeneous,9-cm mass
in the right adrenal gland, and [
111In-DTPA
0] octreotide scintigra-
phy showed an abnormal uptake of the radiotracer in the right
perirenal region, corresponding to the adrenal mass.The patient
underwent laparoscopic surgery and formalin-fixed and paraffin-
embedded samples were studied. The tumour was extensively
characterized by immunohistochemistry and somatostatin recep-
tor (SSTRs) subtypes expression was analyzed. Histological and
immunohistochemical examination of the surgical specimens
displayed a typical pheochromocytoma, which was found to be
immunoreative to S-100, chromogranin A and neurofilaments.
Immunostaining for SSTR subtypes showed a positive reaction for
SSTR1, SSTR2A, SSTR2B, antisera on tumour cells. The
intense and diffuse immunostaining for corticotropin releasing
hormone (CRH) antiserum indicated that Cushing’s disease was
dependent on CRH overproduction by the pheochromocytoma,in
which no immunostaining for adrenocorticotropic hormone was
found. Our report confirms the heterogeneity of the pattern of
SSTR expression in pheochromocytomas,and provide further evi-
dence for functional SSTR subtype SSTR2a in a subgroup of
pheochromocytomas, suggesting that these tumours may repre-
sent potential target for octreotide treatment.
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P
haeochromocytomas are tumours derived
from the chromaffin cells of the sympatho-
adrenal system, generally associated with
cathecolamine overproduction. They represent a
rare condition, occurring in less than 0.2% of
patients with hypertension. The diagnosis of spo-
radic phaeochromocytoma is based on clinical his-
tory and features characterized by the triad
episodic headache, sweating, and tachycardia, but
an increasing number of these tumours are diag-
nosed in patients without classical symptoms
(Pacak et al., 2001). Ectopic Cushing’s syndrome
is one of the possible, albeit unusual, expression of
pheochromocytoma. Up to date, there are few
reports of pheochromocytomas producing adreno-
corticotropic hormone (ACTH) and/or ACTH pre-
cursors (O’Brien T et al.,1992; Chen et al.,1995;
White et al., 2000), and even more limited is the
number of cases in which pheochromocytoma
secrete corticotropin releasing hormone (CRH)
(Eng et al., 1999; Bayraktar et al., 2006).
Similar to other neuroendocrine tumours,
pheochromocytomas often express somatostatin
receptors (SSTR) (De Herder and Hofland,
2004), but data on the specific SSTRs subtypes
expressed within the tumours are thus far sparse
and conflicting and the real therapeutic effective-
ness of somatostatin analogue in these tumours is
still debated (Reubi et al., 1992; Kubota et al.,
1994; Epelbaum  et al., 1995; Hofland  et al.,
1999; Mundschenk  et al., 2003; Unger  et al.,
2004;Ueberberg et al.,2005;Unger et al.,2007).
Materials and Methods
Patient
A 50-year-old woman referred to our Endocrine
Unit for help in the management of severe
REVIEW hypokalaemia and hypertension. At the time of
presentation, she displayed typical Cushing’s fea-
tures. Plasma ACTH and serum cortisol levels
were elevated (73 pmol/L, n.v. 2-11, and 3773
nmol/L, n.v. 215-1000, respectively), without cir-
cadian rhythm (midnight cortisol 2905 nmol/L).
Mean 24-h urinary free cortisol excretion (UFC)
was markedly elevated (1627 nmol/24h; n.v. 206-
744), while plasma and urinary ephinefrine, nor-
metanephrine and metanephrine concentrations
were within the normal range. Serum chromo-
granin A levels were markedly increased (1060
ng/mL; n.v. <100). Abdominal computed tomog-
raphy (CT) demonstrated a 9 cm round mass with
calcifications and central necrosis in the right
adrenal gland. No other abnormalities were
detected either by CT of neck and chest or by
magnetic resonance imaging of the pituitary. A
whole-body scintigraphy (WBS) with [
111In-
DTPA
0] octreotide (Octreoscan
®) showed abnor-
mal uptake in the area corresponding to the adre-
nal mass demonstrated by CT (Figure 1), indicat-
ing expression of the SSTRs by the tumour cells.
Thus, medical treatment with the somatostatin
analog octreotide (0.1 mg s.c. two times daily)
was started. This treatment induced a dramatic
improvement in clinical signs and symptoms,
which was accompanied by rapid normalization of
plasma ACTH, serum cortisol and UFC levels,
serum potassium and glucose levels. When her
clinical condition improved, the patient underwent
surgery.The post-operative course was uncompli-
cated, and hydrocortisone replacement therapy
was not necessary. Clinical features of Cushing’s
syndrome gradually disappeared of all and at the
last follow-up, three years after surgery, the
patient is free of disease.
Histological and immunohistochemical evaluation 
The neoplastic surgical sample was fixed in
10% neutral formalin for 24 hours at room tem-
perature; successively, some representative speci-
mens were embedded in paraffin at 55°C and cut
into 5 µm thick consecutive sections to perform
Haematoxylin-Eosin (H&E) routine histological
stain and immunohistochemical procedures. The
local Ethics Committee approved the experimental
protocol and an informed consent was obtained
from the patient.
The immunohistochemical characterization of
the tumour was performed utilizing, separately,
the following antisera: a) monoclonal antisera
against chromogranin A (working diluition
1:100), neurofilaments (wd 1:100), human Ki-67
antigen (clone MIB-1,wd 1:200) and ACTH (wd)
1:75),(all from DAKO,Carpinteria,CA,USA);b)
polyclonal antisera against S-100 (DAKO, wd
1:300), CRH, and Pro-opiomelanocortin
Precursor (POMC) (all from Abcam, Cambridge,
UK, wd 1:100).
Antigen retrieval procedures (microwave oven
exposure for 3 cycles x 5 min at 100°C,in 10 mM
citrate buffer, pH 6.0) were carried out for the
antisera against ACTH, chromogranin A and
human Ki-67 antigen. A pre-treatment with
pronase (DAKO) 0.05% in phosphate-buffered
saline (PBS) for 5 min at room temperature was
applied before the immunostaining for S-100.The
immunostaining of all antisera, either monoclonal
or polyclonal, was preceded by steps with 0.1%
H2O2 in methanol to block the intrinsic peroxidase
activity and with normal sheep serum to prevent
aspecific adherence of serum proteins;the incuba-
tion was carried out at 4°C for 16 hrs in a moist
chamber. Finally, the biotin-streptavidin-peroxi-
dase method (LSAB2 System-HRP multilink uni-
versal kit from DAKO) was applied.To develop the
reaction, sections were incubated in darkness for
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Figure 1. Coronal plane of the whole-body scintigraphy, performed
4 hours after injection of [
111In-DTPA
0] octreotide, shows abnor-
mal uptake in the area corresponding to the adrenal mass demon-
strated by CT (black arrow) and the normal uptake of right (R)
and left (L) kidneys and of spleen (S).10 min. with 3-3’ diaminobenzidine tetrahy-
drochloride (DAB) (Sigma Chemical Co., St.
Louis,MO,USA),in the amount of 100 mg in 200
ml 0.03% hydrogen peroxide in PBS.The nuclear
counterstaining was performed by Mayer’s
haemalum for 5 min at room temperature; then
slides were dehydrated in ascending ethanols,clar-
ified in xylene and mounted with a synthetic medi-
um (Permount). Negative controls included omis-
sion of the primary antiserum or replacement of
the primary antiserum with normal horse/goat
serum.In each of these conditions,no staining was
evident.Placental fragments at the third trimester
of pregnancy were utilized as positive control tis-
sue for CRH and POMC antisera.An evident reac-
tivity for POMC and CRF was encountered in syn-
cytio-cytotrofoblast cellular layers of placental
tissue.
Immunohistochemical localization of all soma-
tostatin receptors (SSTRs) subtypes was per-
formed on 5 µm paraffin-embedded parallel sec-
tions with the polyclonal antibodies against
human SSTR1, SSTR2A, SSTR2B, SSTR3, SSTR4,
SSTR5 (all from Biotrend, Cologne, Germany; wd:
1:3500).In brief,the sections were pre-treated in
microwave owen in 10 mM citric acid, pH 6.0 (3
cycles for 15 min at 100°C), and incubated over
night (o.n.) at 4°C with each antibody.A standard
streptavidin-biotin-peroxidase (LSAB2 System-
HRP multilink universal kit from DAKO) was used
according to the manufacturer’s instructions to
visualize the bound antibodies, and the reaction
was developed in DAB. Negative controls for
immunochemistry included:1) omission of the pri-
mary antibody and 2) pre-absorption of the anti-
bodies with the respective immunizing receptor
peptide. Peptide fragments of human SSTRS sub-
types, SSTR1, SSTR2A, SSTR2B, SSTR3, SSTR4,
SSTR5 C-term (all from Biotrend, Cologne,
Germany), were used at a concentration of 100
nM, and incubated o.n. at 4°C. A tissue was con-
sidered positive when the immunostaining was
abolished by pre-absorption of the antibody with
the respective peptide antigen. Pancreatic tissue
sections were utilized as positive controls for
SSTRS subtypes antisera.
Results
Histological examination
A 7.8x4.8x5.0 cm adrenal mass with a smooth
grey-yellowish appearance was excised. The cut
surface showed foci of necrosis and haemorrhage
as well as areas of cystic degeneration, with a not
uniform consistency. The tumour tissue was
arranged in sheets, cords or alveolar structures
constituted by neoplastic elements showing round
vesicular nuclei, occasionally pleomorphic, and a
granular, pale eosinophilic, cytoplasm (Figure 2
3
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Figure 2. Histological and immunohis-
tochemical analysis of paraffin-embed-
ded sections from our phaeochromocy-
toma. (A) Haematoxylin-eosin stain.
(B) intense and diffuse cytoplasmic
immunoreactivity for CRH. (C) nega-
tive staining with ACTH antiserum. (D)
intense chromogranin A immunoreac-
tivity. The sections were developed
with 3,3'-diaminobenzidine and coun-
terstained with haematoxylin (magnifi-
cation, 300X).
A
CD
BA), in accordance with the diagnosis of pheocro-
mocytoma. Mitoses were rare and the MIB-1
immunostaining was evident in less than 5% of
neoplastic cells.There was no diffuse growth pat-
tern, cellular atypical mitotic figures, or other
signs of malignancy.
Immunohistochemical characterization
Heterogeneous intensity of positive staining was
appreciable with anti-chromogranin A (Figure 2
B) and anti-neurofilaments, neuroendocrine
tumour markers that are typically expressed by
PHEO. A weak, occasional cytoplasmic immuno-
positivity was observed also with S-100 anti-
serum. An intense, mainly diffuse and homoge-
neous,cytoplasmic immunoreactivity for CRH was
found in the tumour, with a high percentage of
stained cells (>70%)(Figure 2 C), thus indicating
unequivocally that adrenal hyperactivity was CRH
dependent, provided that, in contrast with
increased serum ACTH levels, no immunostaining
for this hormone was apparent (Figure 2 D). Only
a weak immuoreactivity for the ACTH precursor
POMC was found but concerned a low percentage
of cells (<30%) and was not uniform, positive
cells being in contact with less reactive or nega-
tive ones.The immunohistochemical evaluation of
SSTRs expression revealed a positive reaction for
SSTR1, SSTR2A, SSTR2B, on tumour cells (Figure
3). The immunostaining was granular or diffuse,
located in the cytoplasm of the neoplastic ele-
ments, and the intensity of the reaction was mod-
erate to strong. A membranous staining was also
present for the SSTR2a subtype (Figure 3 B).In all
cases, immunostaining could be completely abol-
ished by pre-absorption with 100 nM of the
respective peptide antigens.The other SSTR sub-
types were unreactive.
Discussion
The immunohistochemical expression of SSTR1
and SSTR2a and SSTR2b subtypes in the tumour
cells demonstrated in the tumour of the studied
patient, is correlated with clinical and functional
imaging data ([
111In-DTPA
0] octreotide scintigra-
phy) along with the effect of somatostin analogue
treatment and the outcome of the disease.
SSTRs is a known characteristic of phaeochro-
mocytomas (De Herder and Hofland, 2004), but
information on the specific SSTRS subtypes deter-
mination is lacking. Up to date, few data on the
expression of SSTRS subtypes are available in the
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Figure 3. Positive immunostaining for SSTR1 (panel A), SSTR2A
(panel B) and SSTR2B (panel C) antisera. Note the membranous
immunostaining for the SSTR2a subtype on tumour cells. The sec-
tions were developed with 3,3'-diaminobenzidine and counter-
stained with haematoxylin (magnification, 300X).literature (Reubi et al., 1992; Kubota  et al.,
1994; Epelbaum  et al., 1995; Hofland  et al.,
1999; Mundschenk  et al., 2003; Unger  et al.,
2004; Ueberberg  et al., 2005; Unger  et al.,
2008).
Reubi et al. (1992) for the first time demon-
strated the presence of specific somatostatin
receptors in phaeochromocytomas.They examined
the tumour tissue with regard to the distribution
of SSTR2A receptors, and found that 16 of the18
paraffin-embedded phaeochromocytomas were
stained positive for this SSTR subtype (Reubi et
al.,1992).Kubota and co-workers (1994) detect-
ed SSTR1 and SSTR2 mRNAs in three cases of
phaeochromocytoma, showing an expression pat-
tern identical to that of normal adrenal gland.
Similar results were obtained by Hofland et al.
(1999), who found four of five phaeochromocy-
tomas positive for sst1 and three of five positive
for SSTR2A.
Although the mentioned studies demonstrated
only the expression of SSTR1 and SSTR2, other
Authors investigated the expression pattern of all
five SSTRS subtypes in benign and malignant
phaeochromocytomas. The over-expression of
more than one SSTR subtype (other than the
sst2), such as SSTR1, SSTR3, SSTR4,and/or sst5
receptor subtypes was identified with a prevalence
higher than that of SSTR2 which were found in
less than 50% of these tumours (Epelbaum et al.,
1995; Mundschenk  et al., 2003; Unger  et al.,
2004; Unger  et al., 2008). Epelbaum and co-
workers (Epelbaum et al., 1995) demonstrated in
34 both benign and malignant phaeochromocy-
tomas that mRNAs of all five SSTR subtypes were
measurable in the tumour cells as well as in nor-
mal adrenal tissue, the SSTR2 and SSTR4 being
the most expressed. Indeed, the vast majority (up
to 90%) of the phaeochromocytomas examined
by Mundschenk and Unger showed positive
immunohistochemical staining for SSTR3, in a
high percent (>60%) of tumour cells. Immuno-
reaction for SSTR1, SSTR2a, and SSTR5 receptors
was found in only few tumours and with a lower
expression within each tumour. Particularly,
SSTR2a expression was seen in less than 30% of
phaeochromocytomas (Mundschenk et al., 2003;
Unger  et al., 2004; Unger  et al., 2007). These
observations were partially confirmed by
Ueberberg  et al. (2005), who investigated the
expression of the five SSTRs in various adrenal
tumours and in normal adrenal gland by RT-PCR.
They found that each receptor subtype was
expressed in normal adrenal gland and in more
than 50% of all pheochromocytomas analyzed,
with the SSTR1 being present in nearly all them.
Taken together, these data demonstrate that
SSTR subtypes are expressed in pheochromocy-
tomas with tumor-specific distribution patterns,
and the functional responses to somatostatin ana-
logues depend on a mixed population of receptor.
Unlike classic neuroendocrine tumors, particular-
ly gastroenteropancreatic tumors, charactherized
by SSTR2 over-expression, phaeochromocytoma
may over-express other receptor subtypes, such as
SSTR3 or SSTR1 or SSTR4, for which convention-
al somatostatin analogs have lower affinity. For
this reason, octreotide treatment induced sympto-
matic or hormonal improvements only in few
cases (Invitti et al., 1993; Plouin  et al.,1995;
Kopf et al., 1997; Lamarre-Cliche et al. 2000),
suggesting that octreotide is of limited value for
the treatment of this defined group of patients. It
may be speculated, that other somatostatin ana-
logues – such as pasireotide/SOM230, which has
a broder spectrum than octreotide - may appear
to be more efficient. Indeed, in vitro studies have
shown inhibition of cell proliferation, induction of
apoptosis and reduction of catecholamine secre-
tion (Pasquali et al., 2008), but clinical studies
are necessary to confirm these effects.
Nevertheless, a number of pheochromocytomas
express the SSTR2 receptor and are able to uptake
the radiotracer during octreotide scintigraphy,
representing potential target of treatment with
somatostatin analogs. In our patient, the SST
analog octeotide was able to control hormone
hyper secretion and to improve the patient’s gen-
eral condition. The effectiveness of octreotide
treatment was related to the expression of SSTR
receptors (mainly the SSTR2a subtype), as preop-
eratively suggested by an octreoscan performed
before starting therapy and demonstrated post-
surgically by immunohistochemistry.
Our report confirms the heterogeneity of the
pattern of SSTR expression in pheochromocy-
tomas,and provide further evidence for expression
of functional SSTR subtype SSTR2a in a subgroup
of pheochromocytomas. The SST analog
octreotide can effectively control symptoms
resulting from excessive hormone release and may
be performed to achieve a rapid control of the dis-
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imaging with the [
111In-DTPA
0] octreotide scan
can demonstrate the presence of this specific
receptor subtype on these tumours and may help
to identify those patients who will have a response
to octreotide therapy.
Finally, in our patient, who represent an
unprecedented clinical case, the CRH production
by the phaeochromocytoma was revealed by the
immunohistochemical analysis, that demonstrated
a very strong staining for CRH in the tumour cells,
in the complete absence of ACTH staining. The
CRH secretion by the tumour induced pituitary
hyperfunction, as demonstrated by the promptly
post-surgical recovery of hypothalamic-pituitary-
adrenal axis activity, which made unnecessary
steroid replacement after adrenalectomy.
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